Clinical trial
Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018)
NCT00360737 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018)
- Lead sponsor
- Emergent BioSolutions
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- April 30, 2010
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy